22.10.2025 01:36:52 CEST | Demant A/S |
Intern viden
Selskabsmeddelelse nr. 2025-11 22. oktober 2025
Intern viden
Demant sælger Oticon Medical til Impilo
Demant har i dag underskrevet en aftale om at sælge Oticon Medical til Impilo for en samlet kontraktsum på op til DKK 600 mio. og afslutter dermed processen med at frasælge sit Hearing Implants-forretningsområde. Aftalen sikrer kontinuitet i Oticon Medical-forretningen, virksomhedens fortsat stærke position på markedet, yderligere vækst samt investeringer i fremtidig innovation til gavn for kunder og patienter.
“Jeg er meget glad for, at Impilo overtager ejerskabet af Oticon Medical. Impilo er et nordisk selskab, der har et indgående kendskab til sundhedsområdet – og især medico-området. De har et langsigtet perspektiv, og jeg er sikker på, at Oticon Medical fortsat vil opleve fremgang under det nye ejerskab. Oticon Medical forlader Demant i god form, idet virksomheden har leveret solid vækst igennem årene og for nyligt styrkede sin produktportefølje med lanceringen af flagskibsproduktet Sentio. Demant vil bestræbe sig på at sikre en god overdragelse af virksomheden til gavn for kunder, patienter og medarbejdere,” siger Søren Nielsen, koncernchef & administrerende direktør for Demant.
Som en del af aftalen – og for at sikre forretningskontinuitet – vil Demant i en fastlagt periode supportere Impilo med at udvikle Oticon Medical til at blive en selvstændig virksomhed. Disse overgangsydelser vil omfatte fælles udvikling af den næste generation af produkter, levering af nuværende og fremtidige lydprocessorer, lokal salgs- og kundesupport samt levering af administrative ydelser, indtil disse funktioner er etableret i Oticon Medical.
“Vi er begejstrede over købet af Oticon Medical fra Demant. Under Demants lederskab har Oticon Medical etableret sig som global leder på markedet for benforankrede høresystemer (BAHS) og har vundet hæder for sin innovation og sit urokkelige engagement i forhold til patienterne. Dette opkøb markerer et spændende nyt kapital for Oticon Medical og positionerer dermed virksomheden til endnu større vækst og succes på den lange bane. I tæt samarbejde med Demant ser vi frem til at investere i og fremskynde udviklingen af banebrydende BAHS-løsninger med henblik på at skabe endnu bedre resultater for patienter i hele verden,” siger Fredrik Strömholm, Managing Partner i Impilo.
Finansiel påvirkning og transaktionsoplysninger
Transaktionen omfatter frasalget af Demants Oticon Medical-forretning for en samlet kontraktsum på op til DKK 600 mio. Afhængig af justeringer af nettoarbejdskapitalen og nettogælden betales DKK 325 mio. kontant ved lukning af transaktionen, mens resten af betalingen er betinget af opnåelse af visse målsætninger og milepæle i de kommende år. Provenuet fra salget overføres til koncernens kontante reserver og vil dermed nedbringe koncernens gearing-multipel.
Transaktionen er underlagt sædvanlige closing-betingelser og myndighedsgodkendelser. Lukning af transaktionen forventes at finde sted senest i slutningen af Q1 2026.
Hearing Implants-forretningsområdet (Oticon Medical) indregnes som en del af koncernens ophørende aktiviteter sammen med Communications (EPOS). Vi forventer nu, at underskuddet fra ophørende aktiviteter i 2025 vil være ca. DKK 200 mio. (tidligere et overskud på DKK 0-50 mio.). Ændringen af vores forventninger kan alene henføres til nu gennemførte hensættelser vedrørende aftalte fremtidige ydelser og leverancer, som den positive effekt af overskuddet fra salget af Oticon Medical ikke kompenserer for.
Om Demant
Demant er en af verdens førende koncerner inden for høresundhed og er bygget på en arv af omsorg, sundhed og innovation siden 1904. Koncernen tilbyder innovative teknologier, løsninger og ekspertise, der hjælper mennesker med at høre bedre. Demant er aktiv og engageret i alle aspekter inden for høresundhed – fra hørebehandling og høreapparater til diagnostisk udstyr og serviceydelser. Med hovedsæde i Danmark beskæftiger koncernen over 22.000 medarbejdere globalt og er til stede med høreløsninger i 130 lande, hvor Demant skaber livsændrende forskelle gennem høresundhed. William Demant Fonden ejer aktiemajoriteten i Demant A/S, som er noteret på Nasdaq Copenhagen, hvor aktien er blandt de 25 mest handlede aktier.
Om Oticon Medical
Oticon Medical er en global virksomhed inden for benforankrede høreløsninger, hvis formål det er at bringe lydens kraft til mennesker i alle livets faser. Oticon Medical samarbejder med førende audiologer, kirurger og andre hørespecialister for at støtte og styrke titusindvis af høreimplantatbrugere hver evig eneste dag og sætte dem i stand til at leve livet fuldt ud – nu og i fremtiden.
Om Impilo
Impilo er et førende nordisk investeringsselskab, der udelukkende fokuserer på investeringer i nordiske selskaber inden for sundhedsområdet. Impilo, som blev etableret i 2017, forvalter ca. EUR 2 mia. på vegne af fremtrædende nordiske og internationale investorer. Selskabets kernefilosofi er at skabe bæredygtig og patientorienteret vækst ved at sikre, at selskaberne i deres portefølje yder meningsfulde bidrag til de samfund, markeder og patienter, de betjener. Med kontorer i København og Stockholm er det Impilos formål at fremme innovation og skabe positive, langsigtede resultater på sundhedsområdet.
Yderligere information:
Søren Nielsen, koncernchef & adm. direktør
Telefon +45 3917 7300
www.demant.com
Øvrige kontaktpersoner:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Gustav Høegh, Investor Relations Officer
Henrik Axel Lynge Buchter, External Communication Manager
Kontakter
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
Om Demant A/S
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
Vedhæftninger
2025-11 Demant sælger Oticon Medical til Impilo.pdf
22.10.2025 01:36:52 CEST | Demant A/S |
Inside information
Company announcement no 2025-11 22 October 2025
Inside information
Demant to sell Oticon Medical to Impilo
Today, Demant has signed an agreement to sell Oticon Medical to Impilo for a total contractual consideration of up to DKK 600 million, thereby concluding the process of divesting its Hearing Implants business area. The agreement ensures the continuity of Oticon Medical’s business operations, its sustained strong position in the market, further growth as well as investments in future innovation for the benefit of customers and patients.
“I’m very happy that Impilo is taking over the ownership of Oticon Medical. Impilo is a Nordic company that knows the healthcare – and especially the MedTech – sector very well. They have a long-term perspective, and I’m confident that Oticon Medical will continue to prosper under its new ownership. Oticon Medical is leaving Demant in good shape, as the company has delivered good growth over the years and recently enhanced its product portfolio with the launch of the flagship product, Sentio. Demant is committed to supporting the transition of the business for the benefit of customers, patients and employees,” says Søren Nielsen, President & CEO of Demant.
As part of the agreement – and to ensure business continuity – Demant will support Impilo for a defined period of time, as they develop Oticon Medical into a stand-alone business. These transitional services will include jointly developing next-generation products, supplying existing and future sound processors and providing local sales and customer support as well as administrative services, until such functions are established in Oticon Medical.
“We are thrilled to acquire Oticon Medical from Demant. Under Demant’s leadership, Oticon Medical has established itself as a global leader in the bone anchored hearing systems (BAHS) market, renowned for its innovation and unwavering commitment to patient care. This acquisition marks an exciting new chapter for Oticon Medical, positioning the company for even greater growth and long-term success. In close partnership with Demant, we look forward to investing in and accelerating the development of cutting-edge BAHS solutions to further enhance patient outcomes worldwide,” says Fredrik Strömholm, Managing Partner at Impilo.
Financial impact and transaction details
The transaction involves the divestment of Demant’s Oticon Medical business for a total contractual consideration of up to DKK 600 million. Subject to net working capital and net debt adjustments, DKK 325 million will be paid in cash at closing, with the remaining payment contingent upon achievement of certain targets and milestones in the coming years. The proceeds from the divestment will be added to the Group’s cash reserves and reduce the Group’s gearing multiple.
The transaction is subject to customary closing conditions and regulatory approvals, and closing of the transaction is expected to take place no later than the end of Q1 2026.
Hearing Implants (Oticon Medical) is recognised as part of the Group’s discontinued operations alongside Communications (EPOS). We now expect the loss from discontinued operations to be around DKK 200 million (previously profits of DKK 0-50 million) in 2025. The change in expectations is entirely due to provisions made now for the agreed future services and deliverables, which are not compensated for by the positive effect of the gain on the sale of Oticon Medical.
About Demant
Demant is a world-leading hearing healthcare group built on a heritage of care, health and innovation since 1904. The Group offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries, creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
About Oticon Medical
Oticon Medical is a global company in bone anchored hearing solutions – dedicated to bringing the power of sound to people at every stage of life. Oticon Medical collaborates with leading audiologists, surgeons and other hearing care professionals to empower tens of thousands of hearing implant users every single day, helping them live full lives – now and in the future.
About Impilo
Impilo is a Nordic investment company focused solely on investments in Nordic healthcare companies. Founded in 2017, Impilo manages approximately EUR 2 billion on behalf of prominent Nordic and international investors. The company’s core philosophy is to generate sustainable and patient-centric growth, ensuring that their portfolio companies make meaningful contributions to the societies, markets and patients they serve. With offices in Copenhagen and Stockholm, Impilo is dedicated to fostering innovation and driving positive, long-term outcomes in healthcare.
Further information:
Søren Nielsen, President & CEO
Phone +45 3917 7300
www.demant.com
Other contacts:
René Schneider, CFO
Peter Pudselykke, Head of Investor Relations
Gustav Høegh, Investor Relations Officer
Henrik Axel Lynge Buchter, External Communication Manager
Contacts
Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication & Sustainability, +45 2264 9982, heey@demant.com
About Demant A/S
Demant is a world-leading hearing healthcare group that offers innovative technologies, solutions and expertise to help people hear better. In every aspect, from hearing care and hearing aids to diagnostic equipment and services, Demant is active and engaged. Headquartered in Denmark, the Group employs more than 22,000 people globally and is present with solutions in 130 countries creating life-changing differences through hearing health. William Demant Foundation holds the majority of shares in Demant A/S, which is listed on Nasdaq Copenhagen and among the 25 most traded stocks.
Attachments
2025-11 Demant to sell Oticon Medical to Impilo.pdf
